Breaking News Instant updates and real-time market news.

LYFT

Lyft

$43.75

1.85 (4.42%)

, FB

Facebook

$194.64

1.49 (0.77%)

12:05
11/15/19
11/15
12:05
11/15/19
12:05

JPMorgan adds Lyft to list of top Internet picks

Earlier, JPMorgan analyst Doug Anmuth added Lyft (LYFT) to his list of top picks in the internet sector following third quarter earnings, saying the ride-hailing giant reported "significantly" better than expected revenue and EBITDA as it continues to take share of an increasingly rational U.S. rideshare market, thereby accelerating its path to profitability. Anmuth said that Lyft, which joins Facebook (FB), Amazon (AMZN), and Netflix (NFLX) in his top picks in the sector, also reiterated its expectation for consolidated EBITDA profit by the fourth quarter of 2021, though he continues to believe core rideshare can be profitable "well before that," likely sometime in 2020. The analyst, who has an Overweight rating on Lyft, noted that he removed Twitter (TWTR) and IAC/InterActive (IAC) from his top picks.

LYFT

Lyft

$43.75

1.85 (4.42%)

FB

Facebook

$194.64

1.49 (0.77%)

AMZN

Amazon.com

$1,747.79

-6.92 (-0.39%)

NFLX

Netflix

$293.25

3.57 (1.23%)

TWTR

Twitter

$29.38

0.49 (1.70%)

IAC

IAC

$223.02

2.85 (1.29%)

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

LYFT Lyft
$43.75

1.85 (4.42%)

11/07/19
BOFA
11/07/19
NO CHANGE
Target $44
BOFA
Buy
Uber trading at discount to peers amid lock-up pressure, says BofA/Merrill
BofA Merrill Lynch analyst Justin Post noted that 134M shares of Uber stock traded yesterday, which compares to average daily volume of about 12M shares since its IPO and represents around 9% of the 1.4B shares unlocked by the expiration of the IPO lock-up provisions. The stock's roughly 4% decline was consistent with the recent basket of Internet IPOs he compares it to, which declined 2.3% on average on the day of lock-up expiration, Post added. He thinks lock-up related selling will likely remain a headwind in November, but he also notes that the company's current adjusted market cap of $30.4B implies a valuation discount to GrubHub (GRUB) and Lyft (LYFT). The analyst, who sees support coming from new segment disclosures and sum-of-the-parts valuation despite the lock-up overhang, keeps a Buy rating on Uber shares with a $44 price target.
10/31/19
JPMS
10/31/19
NO CHANGE
Target $85
JPMS
Overweight
Lyft taking share in 'increasingly rational' market, says JPMorgan
Lyft continues to take share of an "increasingly rational" U.S. rideshare market, thereby accelerating its path to profitability, JPMorgan analyst Doug Anmuth tells investors in a post-earnings research note. While Lyft reiterated its expectation for consolidated EBITDA profit by Q4 of 2021, the analyst continues to believe core rideshare can be profitable "well before that," potentially sometime in 2020. The analyst lowered his price target for the shares to $85 from $90 and reiterates an Overweight rating on Lyft.
10/31/19
MKMP
10/31/19
NO CHANGE
Target $50
MKMP
Neutral
Lyft price target raised to $50 from $45 at MKM Partners
MKM Partners analyst Rohit Kulkarni raised his price target on Lyft to $50 but kept his Neutral rating after its Q3 results. The analyst notes that the company's key metrics, like the number of active riders and revenue per rider, trended higher on a sequential basis, but he prefers to remain on the sidelines until there is more clarity around the impact of regulations in New York and San Francisco.
10/31/19
10/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Overweight from Equal Weight at Barclays with analyst Karen Short saying total comp expectations for Q3 may be too high due to the expected drag from Canada as well as ongoing weakness in e-commerce, but believe the U.S. comp estimate of 3.6% "is what matters and is more achievable." 2. Sony (SNE) upgraded to Buy from Neutral at UBS. 3. Ensign Group (ENSG) upgraded to Buy from Hold at Stifel with analyst Chad Vanacore saying he sees a potential real estate spin-off or sale on the horizon. 4. Lyft (LYFT) upgraded to Buy from Neutral at Goldman Sachs with analyst Heath Terry saying the company reported better than expected Q3 revenue and management noted a trend toward higher prices across the industry, incremental engagement per rider, and a less promotional competitive environment. 5. Brinker (EAT) upgraded to Overweight from Neutral at Piper Jaffray with analyst Nicole Miller Regan saygin the company's return to EBITDA growth should drive a re-rating of the multiple. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FB Facebook
$194.64

1.49 (0.77%)

11/05/19
11/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Outperform at Daiwa with analyst Satoshi Tanaka saying the company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns." 2. Beyond Meat (BYND) upgraded to Outperform from Market Perform at Bernstein with analyst Alexia Howard saying she is making a "straightforward valuation call" with the shares down 66% from their peak. 3. NXP Semiconductors (NXPI) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying the company's auto segment is showing signs of recovery, with easier compares and content wins. 4. Amgen (AMGN) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Alethia Young saying recent events have set the stage for a "clean base business and pipeline story" for Amgen in 2020. 5. Autoliv (ALV) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying an improving 2020-2021 auto outlook with easier compares, continued airbag market share gains versus Takata, and lower product launch costs position Autoliv well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/04/19
SPHN
11/04/19
INITIATION
Target $250
SPHN
Overweight
Stephens starts Trade Desk at Overweight, touts model compared to Netflix, Roku
Stephens analyst Kyle Evans initiated coverage of Trade Desk (TTD) with an Overweight rating and $250 price target, stating that he believes investors should own the stock because the company has "a more distributed, defendable and profitable business model" than Netflix (NFLX) or Roku (ROKU) with fewer regulatory risks than Google (GOOGL) or Facebook (FB), although he added that the stock is "volatile and expensive." He sees the catalysts of connected TV tailwinds and international growth outweighing the risks of a premium multiple and the growth of ad-free streaming TV options, Evans added.
11/04/19
DAIW
11/04/19
UPGRADE
DAIW
Buy
Facebook upgraded to Buy from Outperform at Daiwa
11/05/19
DAIW
11/05/19
UPGRADE
Target $250
DAIW
Buy
Daiwa upgrades Facebook to Buy, says earnings concerns 'largely alleviated'
Daiwa analyst Satoshi Tanaka last night upgraded Facebook to Buy from Outperform with a price target of $250, up from $235. The company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns," Tanaka tells investors in a research note. The analyst sees "clearer visibility" from 2020 as well as higher upside after the stock's recent pullback. Facebook's revenue growth slowdown is more moderate than previously anticipated while its guidance for total expenses remains within expectations, contends the analyst. He believes the "negative repercussions" stemming from the implementation of Europe's new data protection regulation and Facebook's data leak "controversy are clearer now that a year has passed." Concerns on the earnings front "have largely been alleviated," says Tanaka.
AMZN Amazon.com
$1,747.79

-6.92 (-0.39%)

11/05/19
RSBL
11/05/19
UPGRADE
Target $13
RSBL
Buy
Applied Optoelectronics upgraded to Buy ahead of guidance at Rosenblatt
As previously reported, Rosenblatt analyst Jun Zhang upgraded Applied Optoelectronics (AAOI) to Buy from Neutral with a price target of $13, up from $10. When the company reports Q3 results tomorrow, Zhang believes it will provide guidance for sequential revenue growth in Q4, powered by Microsoft's (MSFT) increasing demand for 100G products and demand from Amazon (AMZN) for 40G products. In addition to demand in the U.S. hyperscale market, Zhang sees Applied benefiting in 2020 from potential opportunities in 5G, a likely design wins at ZTE (ZTCOY), and potential opportunities to supply to Cisco (CSCO) clients.
11/13/19
NOMU
11/13/19
NO CHANGE
Target $42
NOMU
Neutral
Nike ending direct Amazon sales positive for Dick's, says Nomura Instinet
Nomura Instinet analyst Michael Baker says Nike's (NKE) decision to stop selling product directly to Amazon (AMZN), as reported this morning by Bloomberg, should be positive for Dick's Sporting Goods (DKS). Nike product will still be available on Amazon through its third-party market place, so the good for Dick's "is only modest," Baker tells investors in a research note titled "DKS Winning Online." The analyst believes Dick's is one of Nike's most valuable partners. The company accounts for about 6.6% of Nike's North American sales and 9.6% of its North American wholesale sales, and the penetration has been growing, contends Baker. This makes Dick's Nike's second-biggest wholesale partner, says the analyst, how keeps a Neutral rating on Dick's with a $42 price target.
11/06/19
DADA
11/06/19
NO CHANGE
Target $20
DADA
Buy
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
DA Davidson analyst Tom Forte reiterates a Buy rating on Sonos (SONO) with a $20 price target following Alphabet's (GOOG, GOOGL) acquisition of Fitbit (FIT). The stock in early trading is up 82c to $14.28. The analyst sees Sonos as the most likely company he covers to have its shares rally from either an improvement in investor perception or a takeover. Sonos is the "best house" on the "bad block" of hardware companies, and is "adjacent to the mansion on the neighboring block, Apple (AAPL)," Forte tells investors in a research note. Similar to Apple, Sonos makes products that are superior to the competition, has an eye for design, and boasts a premium brand that enables it to sell its products at higher prices than others, the analyst says. Further, Forte believes that similar to Fitbit not getting proper credit for its healthcare-related efforts, Sonos does not get credit for its superior technology and premium brand. As such, he sees Sonos as a "natural acquisition target for Apple." Furthermore, while less obvious than Apple, Amazon (AMZN) could acquire Sonos to advance its connected home efforts, according to Forte. The analyst also thinks the company could go private given the "lack of appreciation by Wall Street."
10/28/19
COMP
10/28/19
NO CHANGE
COMP
Compass Point says Amazon could challenge Microsoft winning JEDI contract
Compass Point policy analyst Isaac Boltansky said, following the Department of Defense awarding the $10B JEDI contract to Microsoft (MSFT) over Amazon (AMZN), that his channel checks indicated Amazon could challenge the decision. However, he believes that while there will be "a degree of handwringing" about the political issues surrounding the contract, he feels "lawmakers are unlikely to wade too deeply into these waters given the increasing toxicity of the Big Tech conversation in Washington." Boltansky added that the JEDI contract win was a "significant victory for Microsoft," and that it could also yield some benefit for Oracle (ORCL), as it has a cloud interoperability arrangement with Microsoft.
NFLX Netflix
$293.25

3.57 (1.23%)

11/15/19
GDHS
11/15/19
NO CHANGE
GDHS
Gordon Haskett says Ackman, Icahn could be buyer behind Nomura's Netflix stake
Don Bilson, who heads Gordon Haskett's event-driven research team, said in a note prior to the open that Nomura's largest stock purchase last quarter was Netflix (NFLX), noting that the Japanese bank "put Mantle Ridge into Aramark (ARMK) and Carl Icahn into HP (HPQ) via a swap or some sort of options trade that remained on Nomura's books" previously. He speculated Bill Ackman could be the buyer behind Nomura's stakeholding, even "though there is nothing for an activist to do" at Netflix, given it fits the pattern of some other Pershing Square stock investments and Ackman mentioned not long ago that he had built a new, unnamed position. If it's not Ackman, "we suppose it could be Carl Icahn who just proved he knows who to call at Nomura" and his son, who previously got Icahn into the stock, is set to rejoin his fund shortly, Argenti wrote in his pre-open note.
11/13/19
WEDB
11/13/19
NO CHANGE
WEDB
Disney's 'jaw dropping' 10M Disney+ subscribers beats expectations, says Wedbush
Wedbush analyst Daniel Ives said Disney's (DIS) just announced 10 million subscribers for Disney+ is a "jaw dropping" figure that he believes is considerably higher than many on Wall Street were anticipating. He also thinks Disney could hit its long term subscriber target of 60 to 90M by s by 2024 potentially two years earlier at this pace. The company's "unmatched content" and "massive" brand and distribution make Disney+ a "legitimate streaming competitor on Day One" to Netflix (NFLX), Ives added. Commenting on the recent launch of Apple's (AAPL) TV+, Ives said pricing, content, and especially the company's installed base remain its "major strategic weapons."
11/11/19
ARGS
11/11/19
NO CHANGE
Target $160
ARGS
Buy
Disney price target raised to $160 from $143 at Argus
Argus analyst Joseph Bonner raised his price target on Disney (DIS) to $160 and kept his Buy, saying the company posted a 5% growth in consolidated segment operating income in Q4 despite the "financial noise" around its Fox and Hulu acquisitions as well as the boost in spending on DTC streaming video. The analyst notes that this week's launch of Disney+ marks the "cornerstone" of its DTC strategy, adding that while the costs of the strategy are high, it is a necessary move against the surging competition from Netflix (NFLX).
11/05/19
EVER
11/05/19
NO CHANGE
Target $300
EVER
In Line
October app data suggest Netflix subscriber miss in Q4, says Evercore ISI
Following an analysis of October app data points for Netflix, Evercore ISI analyst Lee Horowitz says the company's global downloads grew around 2% in October, down modestly from September, as international growth slowed to 3% versus 6% in September. However, Netflix's U.S. download growth improved, to down 4% in October versus down 10% in September, as a growing film slate "seems to have bolstered the top of the funnel domestically," Horowitz tells investors in a research note titled "A Spooky Start for NFLX 4Q Downloads." The analyst, who cautions against reading too deeply into these results, says the October levels are consistent with "below-guidance" Q4 subscriber results. In addition, while Horowitz expects Martin Scorsese's The Irishman will benefit subscriber growth trends in November, he points out that a geographic analysis of download trends associated with El Camino suggest that U.S. dramatic films "may not materially move the subscriber growth needle in key international growth markets." The analyst keeps an In-Line rating on Netflix with a $300 price target.
TWTR Twitter
$29.38

0.49 (1.70%)

11/11/19
LOOP
11/11/19
NO CHANGE
Target $42
LOOP
Buy
Twitter price target lowered to $42 from $55 at Loop Capital
Loop Capital analyst Alan Gould lowered his price target on Twitter to $42 to reflect its "disappointing setback in monetization", saying the company's software issues in Q3 contributed to a "rather large" revenue shortfall. The analyst warns that these issues are also expected to linger into Q4 but ultimately expects them to be "transitory", keeping his Buy rating on Twitter while citing its accelerating user growth and a "rich slate of events" in 2020.
11/07/19
11/07/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from In Line at Evercore ISI with analyst Kevin Rippey citing his view that 2018 represented a period of "unsustainably high" margins as Twitter reaped the benefits of a period of sustained underinvestment. 2. Mylan (MYL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger sayinge has become more conservative in his estimates after competing U.S. generic businesses missed estimates in the past two days, which he thinks may be indicative of ongoing industry pressures. 3. Expedia (EXPE) downgraded to Neutral from Overweight at Piper Jaffray and to Neutral from Buy at DA Davidson and BofA/Merrill. 4. Bloomin' Brands (BLMN) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe citing valuation. 5. Papa John's (PZZA) downgraded to Neutral from Buy at MKM Partners with analyst Brett Levy saying the company has generated its first positive domestic comps in two years while laying the foundation for a "potential turnaround," but after a 43% run-up in the stock price since August 23, he believes the valuation warrants a neutral stance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/19
BOFA
11/07/19
NO CHANGE
Target $39
BOFA
Buy
Twitter set-up well for 2020 despite 'privacy misstep' in Q3, says BofA/Merrill
BofA Merrill Lynch analyst Justin Post noted that Twitter's data privacy and targeting issues hurt Q3 revenues and he expects those issues to remain an overhang in Q4. However, he thinks user growth and improving engagement trends were positives possibly "lost" amid Q3's privacy misstep and he sees Twitter's ongoing product changes providing a "healthy backdrop" for 2020, which will feature a strong events calendar. Post reiterates his Buy and $39 price target on Twitter shares.
11/07/19
EVER
11/07/19
DOWNGRADE
Target $25
EVER
Underperform
Twitter downgraded to Underperform on expense growth pressure at Evercore ISI
Evercore ISI analyst Kevin Rippey downgraded Twitter to Underperform from In Line with a price target of $25, down from $42, citing his view that 2018 represented a period of "unsustainably high" margins as Twitter reaped the benefits of a period of sustained underinvestment. While he thinks the "bugs" that plagued Q3 results can be addressed in coming quarters, Rippey thinks Twitter will likely need to grow R&D spending at rates faster than those of revenue if the company hopes to approach the level of long-term revenue growth implied by consensus, the analyst tells investors. Expense growth pressure is Twitter's "new reality," Rippey concludes.
IAC IAC
$223.02

2.85 (1.29%)

11/08/19
DBAB
11/08/19
NO CHANGE
Target $256
DBAB
Buy
IAC price target lowered to $256 from $279 at Deutsche Bank
Deutsche Bank analyst Kunal Madhukar lowered his price target for IAC (IAC) to $256 from $279 and keeps a Buy rating on the shares. IAC delivered a "solid quarter," with the core businesses of Vimeo, Dotdash, and Mosaic "reaching critical revenue milestones," and Angi Homeservices' (ANGI) sales growth came in better than feared, Madhukar tells investors in a research note.
11/12/19
GUGG
11/12/19
NO CHANGE
Target $270
GUGG
Buy
IAC price target lowered to $270 from $300 at Guggenheim
Guggenheim analyst Jake Fuller lowered his estimates for IAC (IAC) to account for Q3 results and guidance, noting that results were largely in line, but the Q4 EBITDA guidance was below consensus. He also said in his note to investors that he estimates an IAC shareholder would get about $156 per share in Match Group (MTCH) stock and net cash would increase by $30-$38 per share, depending on the scale of a Match dividend if a spinoff goes forward. He lowered his price target on IAC shares to $270 from $300, mainly due to the reduction in the market value of Match and Angi Homeservices (ANGI) since the beginning of August. Fuller keeps a Buy rating on IAC shares.
11/11/19
OPCO
11/11/19
NO CHANGE
Target $270
OPCO
Outperform
IAC price target lowered to $270 from $310 at Oppenheimer
Oppenheimer analyst Jason Helfstein lowered his price target for IAC (IAC) to $270 from $310 based on reduced Angi Homeservices (ANGI) and Match Group (MTCH) targets, but keeps his Outperform rating on 22% upside potential. Looking ahead, Helfstein expects investors to now dig into the remaining pieces of IAC stub, namely Vimeo and Dotdash, which both posted accelerating revenue growth of 29% and 34%, respectively, and speculate on M&A vs. share repurchases.
11/08/19
JPMS
11/08/19
DOWNGRADE
Target $245
JPMS
Neutral
IAC downgraded to Neutral on close of valuation gap at JPMorgan
JPMorgan analyst Doug Anmuth downgraded IAC (IAC) to Neutral from Overweight with a price target of $245, down from $300. IAC's announced potential Match Group (MTCH) distribution served as a catalyst for the shares, and the valuation gap between the two "has closed meaningfully within a short amount of time," Anmuth tells investors in a research note. The analyst believes it may take multiple quarters for investors to give more credit to IAC's remaining assets including Vimeo, Dotdash, Mosaic, Bluecrew, and others. Anmuth keeps a Neutral rating on Match and lowered his price target for the shares to $75 from $93. He also keeps an Overweight rating on Angi Homeservices (ANGI) with a $14 price target.

TODAY'S FREE FLY STORIES

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.